Navigation Links
TrovaGene Acquires CLIA - Certified Laboratory
Date:1/6/2012

ction of mutations in samples with heterogeneous genomes."

About TrovaGene, Inc.

Headquartered in San Diego, California, TrovaGene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

TrovaGene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML).

TrovaGene has filed a Form 10 with the SEC. More complete current information about TrovaGene is contained in the filing.

About MultiGEN

MultiGEN continues to operate as a molecular diagnostics company focused on DNA sequence based identification services having IP protected technologies. Using the well-documented 'Gold-Standard' accuracy of DNA sequencing, MultiGEN is able to provide 'Syndrome Driven Panels' in a single test that screens for all the pathogens or mutations that can cause a particular syndrome regardless of whether they are bacteria, viruses, fungi or parasites. MultiGEN does this with same-day reporting to better assist with the timely creation of an optimal treatment regime. MultiGEN's other two groups of applications include developing highly sensitive assays to detect mutations among samples carrying heterogeneous genomes and applications in drug development.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These for
'/>"/>

SOURCE TrovaGene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
2. Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation
3. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
4. IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri
5. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
6. Neogen Acquires VeroMara from GlycoMar Ltd.
7. Healthpoint Biotherapeutics Acquires Regranex® Gel
8. VWR International, LLC Acquires BioExpress Corp.
9. Watson Acquires Specifar Pharmaceuticals
10. Sigma-Aldrich Acquires Vetec Quimica Fina Ltda
11. PRA International Acquires Key Software Developer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... - Continued Advancement Toward Goal of ... Shire (LSE: SHP, NASDAQ: SHPG ) announces ... 2015. Financial Highlights Q1 2015 Growth(1) ... $1,488 million +11% +15% Non GAAP operating income $683 ... operations $475 million +55% Non GAAP EBITDA margin (excluding ...
(Date:4/30/2015)... 2015 Available in select spas ... , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream ... while battling the weakening threat of inflammaging, aging ... formulated with star ingredient GLYCOSEA, a complex of ... complex of soothing minerals and trace elements. GLYCOSEA ...
(Date:4/30/2015)... Sterlitech is proud to offer Synder ... PY, and PZ Polyacrylonotrile (PAN) membranes , as ... to be ideal for oil removal in wastewater ... process requirements where the presence of oils in ... on industrial wastewater discharge and quality requirements for ...
(Date:4/29/2015)... 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today ... 2014. Biorem,s complete fiscal 2014 year-end financial statements and MD&A have been ... , 2013 , 2014 , 2013 Revenue ... 19,596 Gross profit 1,326 , 1,703 , 2,231 ... 1,493 , 3,377 , 4,562 Ebitda* 92 ...
Breaking Biology Technology:Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Sterlitech Offers New Ultrafiltration Membranes 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... applications for the real world, has formalized ... Inc. One of the many businesses that ... Tier 1 automotive supplier focusing on technology-rich ... and Lumidigm will bring patented biometric functionality ...
... N.J., Aug. 5 Ortho Biotech is announcing,that it is voluntarily ... cracks in the necks of a,small number of vials upon post-manufacturing ... Approximately 44,292 vials of lot,P114942A in the following packaging configurations were ... NDC ...
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial ... 2008., Replidyne reported a net loss of $18.7 million ... per basic and diluted common share of $0.69,per share, compared ... share or $1.65 per common share on a fully diluted ...
Cached Biology Technology: Lumidigm Signs Strategic Agreement with Methode Electronics : Automotive Supplier Invests in Biometric Component Development 2Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A 2Replidyne Announces Second Quarter 2008 Results From Operations 2Replidyne Announces Second Quarter 2008 Results From Operations 3Replidyne Announces Second Quarter 2008 Results From Operations 4Replidyne Announces Second Quarter 2008 Results From Operations 5Replidyne Announces Second Quarter 2008 Results From Operations 6Replidyne Announces Second Quarter 2008 Results From Operations 7
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... American Pregnancy Association, six million women a year deal with ... hope to women who want to conceive ― in the ... shelves right now. Prof. Adrian Shulman of Tel Aviv ... has found a statistical connection between the over-the-counter vitamin supplement ...
... at the Living Planet Symposium have been hearing about ... almost three months, the satellite is in excellent health ... presented at the symposium. Prof. Duncan Wingham, Lead ... in very good shape exceeding in-orbit specifications, the ...
... study of the occurrence of fishes in the ocean,s deepest ... species of fishes are more numerous at such depths than ... published in the July/August issue of BioScience , observed ... meters around a baited video lander in the Japan Trench. ...
Cached Biology News:Increasing fertility threefold 2CryoSat-2 exceeding expectations 2Study suggests more fish than thought may thrive in the ocean's depths 2
...
Use as the souce of CETP enzyme for screening CETP inhibitors. Use in conjunction with the CETP activity assay kit (K601-100)....
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Biology Products: